Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.
about
Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutationThe role of oxidative stress in Parkinson's diseaseFunctional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamilyHexokinase activity is required for recruitment of parkin to depolarized mitochondriaThe Application of Human iPSCs in Neurological Diseases: From Bench to BedsideThe Progress of Induced Pluripotent Stem Cells as Models of Parkinson's DiseaseEnergy Metabolism Plays a Critical Role in Stem Cell Maintenance and DifferentiationInduced pluripotent stem cells for modeling neurological disordersEpigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based ModelsInduced pluripotent stem cells in Parkinson's disease: scientific and clinical challengesMitochondria: A Therapeutic Target for Parkinson's Disease?Using iPS Cells toward the Understanding of Parkinson's DiseaseNovel subcellular localization for α-synuclein: possible functional consequencesConcise review: Generation of neurons from somatic cells of healthy individuals and neurological patients through induced pluripotency or direct conversionProgramming and Reprogramming Cellular Age in the Era of Induced PluripotencyHeterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implicationsThe role of the LRRK2 gene in ParkinsonismCell-based screening: extracting meaning from complex data.Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in miceMfn2 is Required for Mitochondrial Development and Synapse Formation in Human Induced Pluripotent Stem Cells/hiPSC Derived Cortical NeuronsiPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's diseasePhysiological characterisation of human iPS-derived dopaminergic neuronsAdvances in Stem Cell Research- A Ray of Hope in Better Diagnosis and Prognosis in Neurodegenerative DiseasesLRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesUtilizing induced pluripotent stem cells (iPSCs) to understand the actions of estrogens in human neuronsConcise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegenerationCreation of an open-access, mutation-defined fibroblast resource for neurological disease research.Solving the puzzle of Parkinson's disease using induced pluripotent stem cells.Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons.Generation of induced Pluripotent Stem Cells as disease modelling of NLSDMInduced Pluripotent Stem Cells: Global Research Trends.Creation of a library of induced pluripotent stem cells from Parkinsonian patients.Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis.Coenzyme q10 therapyRNA metabolism in the pathogenesis of Parkinson׳s diseaseMsp1/ATAD1 maintains mitochondrial function by facilitating the degradation of mislocalized tail-anchored proteinsAccelerating neuronal aging in in vitro model brain disorders: a focus on reactive oxygen speciesInvestigating human disease using stem cell models.Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplicationEarly-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study
P2860
Q24297033-122B9B2D-FF1C-4A64-A05F-6BD2BA229C21Q24307946-A6FEBB6B-A58C-477E-87A1-AEA0BEBE0205Q24310218-899A6D2F-8C92-40F2-B8A5-C50D0B109193Q24318901-925372F2-70C9-4595-97FA-F4A788B9759FQ26765876-A7786D80-A403-4A49-84C1-61264D6F63BCQ26765894-FE10C80D-FFB4-4DEA-BACA-F93D7D4F5AA6Q26768456-66F7DBBD-081A-4E80-9D71-AE46EA1F6BF9Q26771402-B5DAE778-B0F5-439A-A431-B9A2964EEEBBQ26772307-78C681FD-C5CC-4EE4-9394-0EBA9B4D332EQ26772879-E7843C81-9883-42DE-9B6A-0B4882C9495BQ26784216-EAEB9BB9-6FB6-4E32-BAB1-A27786040EBBQ26799590-6852C65B-C34C-42A1-ACB0-025239A0BAFEQ26827605-BD96DEF2-8D00-43BE-BA40-AEA23CEA1B40Q27004350-027B3DA5-6363-4375-A106-97431715297CQ27008903-B156FCCB-C0E2-4DE9-8051-7DEAC7B849FBQ27013695-6DA6656C-D911-464B-B364-82C1E81EC133Q27023749-ECE97E3E-1A55-4574-8D52-1BE3BD688FA9Q27305816-69E19C43-4687-4455-90B8-1F0007B1A3F3Q27308060-A0AC949B-0462-4AA3-8389-AEFFB27BAE44Q27318046-71B462ED-C125-4C4B-A94D-B0CFB49AB1B1Q27321433-949EC64B-37DA-47D5-AF3B-11776F8446CBQ27324718-E59100D7-0190-49A2-B46B-FBE41C9487B3Q28067160-71071C5A-1AC9-4C32-86A1-58442D7B3041Q28078899-EE318616-9947-4037-8526-C5AAFBDED8A4Q28081565-A57B03A2-EEEE-4D0B-9505-7FD3A9A25068Q28649438-4E024940-E52D-4A18-B66D-5C6859CEE3A6Q30485675-507DB660-A5B7-42B7-A8B2-B3AEB5E6D276Q33358637-E5E9F4C2-D982-46F6-950A-80168F76605CQ33616462-02AA6ED7-55A2-499E-9ABF-E339A8B26826Q33695645-E718A3F0-5AA9-4AC5-8D36-2F408A586C99Q33914515-72DC4B48-7AD0-4479-A789-6FA93AED120EQ33917317-2602E194-9DCE-4F43-AD4F-FE34CA485C84Q33925831-B5A1C3A2-DCF4-4FC6-8FC3-F4567E59FB01Q33956936-FCD64EC7-9AC6-43DC-9B42-E96339490533Q34175642-F99C2001-0515-4D48-82B4-25E1AB3ADF16Q34343289-B4122267-1369-45BF-981A-7C716D1392A4Q34406924-1AACA7EE-A850-4104-BD47-D97B14430630Q34431170-206EC02D-D382-43C8-BC3A-5A899A7092ABQ34497765-A7802501-63C4-4787-B870-61A5B6312232Q34617223-C4FBAF8B-1B77-4B45-B1B2-A57B778B66C7
P2860
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pharmacological rescue of mito ...... h familial Parkinson's disease
@nl
Pharmacological rescue of mito ...... familial Parkinson's disease.
@ast
Pharmacological rescue of mito ...... familial Parkinson's disease.
@en
Pharmacological rescue of mito ...... familial Parkinson's disease.
@en-gb
type
label
Pharmacological rescue of mito ...... h familial Parkinson's disease
@nl
Pharmacological rescue of mito ...... familial Parkinson's disease.
@ast
Pharmacological rescue of mito ...... familial Parkinson's disease.
@en
Pharmacological rescue of mito ...... familial Parkinson's disease.
@en-gb
prefLabel
Pharmacological rescue of mito ...... h familial Parkinson's disease
@nl
Pharmacological rescue of mito ...... familial Parkinson's disease.
@ast
Pharmacological rescue of mito ...... familial Parkinson's disease.
@en
Pharmacological rescue of mito ...... familial Parkinson's disease.
@en-gb
P2093
P2860
P50
P921
P3181
P1476
Pharmacological rescue of mito ...... familial Parkinson's disease.
@en
P2093
Carol Moskowitz
D James Surmeier
Dimitri Krainc
Eduardo Perez-Torres
Grzegorz Opala
Gunnar Hargus
Helle Bogetofte
Houbo Jiang
Hyemyung Seo
Jesse R McLean
P2860
P304
P3181
P356
10.1126/SCITRANSLMED.3003985
P407
P50
P577
2012-07-01T00:00:00Z